Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
Immix Biopharma, Inc. (Nasdaq:IMMX)
Format
PNG
Quelle:
Immix Biopharma, Inc.